The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.

Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

The present invention provides methods and compositions for screening, diagnosis and prognosis of HCC, glioblastoma and lung cancer, for monitoring the effectiveness of HCC, glioblastoma and lung cancer treatment, and for drug development.

It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula: ##STR00001##
or salts thereof, wherein n is an integer from 12 to 24; and R.sub.2 is —N.sup.+(CH.sub.3).sub.3. The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R.sub.1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection/imaging applications, R.sub.1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.

The present invention relates to a method for the prognosis of bone metastasis in cancer which comprises using a probe to determine if a gene of interest is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise using a probe to determine the expression level of a gene of interest, or the amplification or translocation of a gene of interest. The invention also relates to a method for predicting early bone metastasis in a subject suffering cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of cancer metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering cancer and for classifying a subject from cancer into a cohort.

The present invention concerns methods of diagnosing and treating a malignant neoplasm of the CNS by detecting mammalian tissue expressing integrin alpha 10 subunit or a fragment or variant thereof, and administering a drug specific for integrin alpha 10 subunit.

The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.

The present invention relates to a method for detecting cancer, comprising measuring the expression of a polypeptide having a reactivity of binding to an antibody against a CAPRIN-1 protein having an amino acid sequence shown in any one of the even-numbered SEQ ID NOS: 2-30 in the Sequence Listing via an antigen-antibody reaction in a sample separated from a living organism, and, a reagent for detecting a cancer comprising the CAPRIN-1 protein or a fragment thereof, an antibody against the CAPRIN-1 protein or a fragment thereof, or a polynucleotide encoding the CAPRIN-1 protein or a fragment thereof.

A sensor for liquid biopsy, its method of making, and its method of non-invasive use. The sensor includes a substrate with a surface functionalized with biotinylated antibodies. The biotinylated antibodies are arranged to engage with surface proteins on exosomes associated with malignant cancer cells such as glioma cells.

Materials and methods for treating cancer, including materials and methods for treating cancer in patients identified as having elevated levels of Bim.